Arezoo Asadi1, Milad Abdi1, Ebrahim Kouhsari2, Pegah Panahi3, Mohammad Sholeh1, Nourkhoda Sadeghifard4, Taghi Amiriani5, Alireza Ahmadi6, Abbas Maleki4, Mehrdad Gholami7. 1. Department of Microbiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran. 2. Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran; Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran. Electronic address: Kouhsari-E@medilam.ac.ir. 3. Department of Microbiology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. 4. Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran. 5. Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran. 6. Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran. 7. Department of Microbiology and Virology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Abstract
OBJECTIVES: The increasing crisis regarding multidrug-resistant (MDR) and extensively drug-resistant microorganisms leads to appealing therapeutic options. METHODS: During the last 30 years, minocycline, a wide-spectrum antimicrobial agent, has been effective against MDR Gram-positive and Gram-negative bacterial infections. As with other tetracyclines, the mechanism of action of minocycline involves attaching to the bacterial 30S ribosomal subunit and preventing protein synthesis. RESULTS: This antimicrobial agent has been approved for the treatment of acne vulgaris, some sexually transmitted diseases and rheumatoid arthritis. Although many reports have been published, there remains limited information regarding the prevalence, mechanism of resistance and clinical effectiveness of minocycline. CONCLUSION: Thus, we summarize here the currently available data concerning pharmacokinetics and pharmacodynamics, mechanism of action and resistance, antibacterial activity and clinical effectiveness of minocycline.
OBJECTIVES: The increasing crisis regarding multidrug-resistant (MDR) and extensively drug-resistant microorganisms leads to appealing therapeutic options. METHODS: During the last 30 years, minocycline, a wide-spectrum antimicrobial agent, has been effective against MDR Gram-positive and Gram-negative bacterial infections. As with other tetracyclines, the mechanism of action of minocycline involves attaching to the bacterial 30S ribosomal subunit and preventing protein synthesis. RESULTS: This antimicrobial agent has been approved for the treatment of acne vulgaris, some sexually transmitted diseases and rheumatoid arthritis. Although many reports have been published, there remains limited information regarding the prevalence, mechanism of resistance and clinical effectiveness of minocycline. CONCLUSION: Thus, we summarize here the currently available data concerning pharmacokinetics and pharmacodynamics, mechanism of action and resistance, antibacterial activity and clinical effectiveness of minocycline.
Authors: David M P De Oliveira; Brian M Forde; Minh-Duy Phan; Bernhard Steiner; Bing Zhang; Johannes Zuegg; Ibrahim M El-Deeb; Gen Li; Nadia Keller; Stephan Brouwer; Nichaela Harbison-Price; Amanda J Cork; Michelle J Bauer; Saleh F Alquethamy; Scott A Beatson; Jason A Roberts; David L Paterson; Alastair G McEwan; Mark A T Blaskovich; Mark A Schembri; Christopher A McDevitt; Mark von Itzstein; Mark J Walker Journal: mBio Date: 2022-01-11 Impact factor: 7.867
Authors: Michael D Huband; Jennifer D Thompson; Nabina D Gurung; Qingmei Liu; Li Li; Jay Zhang; Jennifer M Streit; Mariana Castanheira Journal: Antimicrob Agents Chemother Date: 2021-10-11 Impact factor: 5.191